Bio-Connect

PD-L1 antibody [29E.2A3]

GTX01495
GeneTex
ApplicationsFlow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetCD274
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    PD-L1 antibody [29E.2A3]
  • Delivery Days Customer
    9
  • Application Supplier Note
    *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    29E.2A3
  • Concentration
    0.5 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID29126
  • Target name
    CD274
  • Target description
    CD274 molecule
  • Target synonyms
    ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1, programmed cell death 1 ligand 1, B7 homolog 1, CD274 antigen, PDCD1 ligand 1
  • Host
    Mouse
  • Isotype
    IgG2b
  • Protein IDQ9NZQ7
  • Protein Name
    Programmed cell death 1 ligand 1
  • Scientific Description
    This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Chen JY, Li CF, Lai YS, et al. Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth. Br J Cancer. 2021,124(2):484-493. doi: 10.1038/s41416-020-01112-z
    Read this paper
  • Baruah P, Bullenkamp J, Wilson POG, et al. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Front Immunol. 2019,10:1644. doi: 10.3389/fimmu.2019.01644
    Read this paper
  • Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014,74(3):665-74. doi: 10.1158/0008-5472.CAN-13-0992
    Read this paper
  • Lauden L, Boukouaci W, Borlado LR, et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ Res. 2013,112(3):451-64. doi: 10.1161/CIRCRESAHA.112.276501
    Read this paper
  • Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003,170(3):1257-66.
    Read this paper
  • Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001,2(3):261-8.
    Read this paper